Eris Lifesciences Ltd

Eris Lifesciences Ltd has announced its 20th Annual General Meeting (AGM) scheduled for Friday, September 25, 2026, at 11:00 AM IST, to be conducted via Video Conferencing (VC). The company has also released its Annual Report for the Financial Year 2025-26. Both the Annual Report and the Notice of AGM are available on the company's website. The report includes sections on corporate overview, financial highlights, business segments, R&D, manufacturing, and ESG initiatives.

Eris Lifesciences Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, along with an independent reasonable assurance statement. The report details the company's corporate identity, registered and corporate office information, and contact details for BRSR queries. It outlines the company's business activities, primarily pharmaceutical manufacturing and marketing, which account for 100% of its turnover. The report also covers operational details, employee statistics, and market reach, emphasizing its domestic focus with no export activities. The assurance provider for the BRSR Core KPIs is B Kabra and Co, who provided reasonable assurance.

Eris Lifesciences Limited has announced its Twentieth Annual General Meeting (20th AGM) will be held on Friday, September 25, 2026, at 11:00 AM IST via video conferencing. The meeting will address ordinary business, including the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, and the re-appointment of a director retiring by rotation. Special business includes ratifying the remuneration of Cost Auditors for FY27 and re-appointing Mr. Sujesh Vasudevan as an Independent Director for a second term.

Eris Lifesciences Ltd announced that its Board of Directors, in a meeting held on August 31, 2026, approved the re-appointment of Mr. Sujesh Vasudevan as an Independent Director for a term of 5 years, commencing July 25, 2027. The Board also approved convening the 20th Annual General Meeting on September 25, 2026. The meeting of the Board of Directors was held from 10:30 AM to 11:00 AM.

Eris Lifesciences Ltd has drawn down a working capital term loan of ₹64,40,00,000/- from Axis Bank Limited. The purpose of this loan is to meet other short-term liabilities. The company stated that its aggregate debt level will remain unchanged following this transaction. The loan agreement details, including parties, purpose, size, and terms, have been disclosed as per SEBI regulations. The loan is a working capital term loan, and the sanction letter was executed on August 5, 2026. The bank will hold a second charge on assets already created for existing working capital facilities.

Eris Lifesciences Ltd announced that its Board of Directors, in a meeting held on July 29, 2026, approved and took on record the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also submitted the limited review report with unmodified opinions and details as per Regulation 52(4) of SEBI Listing Regulations. Additionally, the Board re-appointed M/s Kiran J. Mehta & Co. as the Cost Auditors for the financial year 2026-27. The board meeting commenced at 11:30 A.M. and concluded at 01:00 P.M.

Eris Lifesciences opened FY27 with a steady, on-plan quarter. Consolidated revenue from operations rose ~13% YoY to ₹873.25 Cr (Q1 FY26: ₹773.00 Cr) and net profit climbed ~14.6% to ₹143.32 Cr (₹142.39 Cr attributable to owners), with EPS at ₹10.28 versus ₹8.66 a year ago. There were no exceptional items this quarter on either side of the YoY comparison, so reported growth is also the underlying growth — a clean double-digit print rather than a flattered one. The headline QoQ decline (PAT down ~49% from Q4 FY26's ₹279.10 Cr) is an accounting artifact, not an operating one: Q4 carried a roughly ₹132 Cr consolidated deferred-tax write-back (total tax was negative that quarter) tied to remeasurement at the revised tax rate. Stripped of that, sequential revenue actually grew ~15% and the operating trend is intact. The margin story is the one to watch: disclosed operating margin eased to 25.94% from 27.02% a year ago, and EBITDA margin softened to ~34% from ~36%, sitting on higher employee costs (₹153.42 Cr) and other expenses (₹184.36 Cr) — the launch-related spend management flagged. NPM held roughly flat YoY at 16.41% (vs 16.18%). This maps directly onto guidance: on the Q4 call management guided FY27 consolidated EBITDA margin ~36% with H1 explicitly softer on launch expenses and improvement pushed to H2 via insourced manufacturing and new launches — and that is exactly the shape of this print. No formal quarterly consensus was available (results dropped the same day as the board meeting), so there is no street beat/miss to score against. Alongside results, the board re-appointed Kiran J. Mehta & Co. as cost auditors for FY27; the ₹7.21 interim dividend was declared earlier on May 20. Standalone tells a different, smaller-entity story (PAT ₹48.30 Cr on ₹443.99 Cr revenue) because most operations now sit in subsidiaries — the consolidated basis is the right read.

Eris Lifesciences Ltd has announced that its Board of Directors will convene on July 29, 2026. The primary agenda item for this meeting is to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. The company also noted that the trading window, which commenced on July 1, 2026, will remain closed until 48 hours after the declaration of these financial results, in compliance with SEBI regulations.

Eris Lifesciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from July 01, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter ending June 30, 2026. All concerned individuals are advised not to trade in the company's securities during this period. This notice is independent of any other trading window closure announcements.

Eris Lifesciences Ltd has released a corporate presentation detailing its business segments, including Domestic Branded Formulations and International Business. The company highlights its strong market position in Anti-Diabetes therapy and Insulins, with a 6% and 16% market share respectively. It also notes a strong start for its Gx Semaglutide brand, Sundae. The presentation outlines significant investments and leveraged acquisitions totaling over ₹4,300 crore between FY23-FY26, aimed at entering high-value therapies and expanding its business, including recent entries into the Derma segment and acquisitions of injectable and other businesses. The company also emphasizes its R&D capabilities and state-of-the-art manufacturing facilities.